Application of Gene Therapy for Parkinson's Disease: Nonhuman Primate Experience

Advances in Pharmacology

Volumn 42, Issue C, 1997, Pages 801-806

  Bankiewicz, K S ^a   Bringas, J R ^a   McLaughlin, W ^a   Pivirotto, P ^a   Hundal, R ^a   Yang, B ^a   Emborg, M E ^a   Nagy, D ^a  

^a CELL GENESYS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956740462     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60868-6     Document Type: Article

References (4)

1. Chase T.N., Juncos J., Serrati C., Fabbrini G., and Bruno G. Fluctuations in response to chronic levodopa treatment of therapy: Pathogenic and therapeutic considerations. In: Yahr M.D., and Bergman K.J. (Eds). Advances in Neurology: Parkinson's Disease (1986), Raven Press, New York 477-480
2. Freese A., Stern M., Kaplitt M.G., O'Connor W., Abbey M., O'Connor M.J., and During M.J. Prospects for gene therapy in Parkinson's disease. Mov. Disord. 5 (1996) 469-488
3. Muzyczka N. Use of adeno-associated virus as general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158 (1992) 97-129
4. Bankiewicz K.S., Snyder R., Zhou S.Z., Morton M., Conway J., and Nagy D. Adeno-associated (AAV) viral vector-mediated gene delivery in non-hurnan primates. Soc. Neurosci. Abstr. 22 (1996) 768